Show simple item record

dc.contributor.authorOzyigit, Gokhan
dc.contributor.authorOnal, Cem
dc.contributor.authorIgdem, Sefik
dc.contributor.authorAlicikus, Zumre Arican
dc.contributor.authorIribas, Ayca
dc.contributor.authorAkin, Mustafa
dc.contributor.authorYalman, Deniz
dc.contributor.authorCetin, Ilknur
dc.contributor.authorAksu, Melek Gamze
dc.contributor.authorAtalar, Banu
dc.contributor.authorDincbas, Fazilet
dc.contributor.authorHurmuz, Pervin
dc.contributor.authorGuler, Ozan Cem
dc.contributor.authorAydin, Barbaros
dc.contributor.authorSert, Fatma
dc.contributor.authorYildirim, Cumhur
dc.contributor.authorGorken, Ilknur Birkay
dc.contributor.authorAgaoglu, Fulya Yaman
dc.contributor.authorKorcum, Aylin Fidan
dc.contributor.authorYüce, Deniz
dc.contributor.authorOzkok, Serdar
dc.contributor.authorDarendeliler, Emin
dc.contributor.authorAkyol, Fadil
dc.date.accessioned2020-03-05T07:46:28Z
dc.date.available2020-03-05T07:46:28Z
dc.date.issued2019
dc.identifier.issn0179-7158en_US
dc.identifier.urihttps://link.springer.com/article/10.1007%2Fs00066-019-01476-z
dc.identifier.urihttp://hdl.handle.net/11727/4591
dc.description.abstractPurpose To validate the clinical outcomes and prognostic factors in prostate cancer (PCa) patients with Gleason score (GS) 8-10 disease treated with external beam radiotherapy (EBRT)+ androgen deprivation therapy (ADT) in the modern era. Methods Institutional databases of biopsy proven 641 patients with GS 8-10 PCa treated between 2000 and 2015 were collected from 11 institutions. In this multi-institutional Turkish Radiation Oncology Group study, a standard database sheet was sent to each institution for patient enrollment. The inclusion criteria were, T1-T3N0M0 disease according to AJCC (American Joint Committee on Cancer) 2010 Staging System, no prior diagnosis of malignancy, at least 70Gy total irradiation dose to prostate +/- seminal vesicles delivered with either three-dimensional conformal RT or intensity-modulated RT and patients receiving ADT. Results The median follow-up time was 5.9 years (range 0.4-18.2 years); 5-year overall survival (OS), biochemical relapse-free survival (BRFS) and distant metastases-free survival (DMFS) rates were 88%, 78%, and 79%, respectively. Higher RT doses (>= 78Gy) and longer ADT duration (>= 2 years) were significant predictors for improved DMFS, whereas advanced stage was a negative prognosticator for DMFS in patients with GS 9-10. Conclusions Our results validated the fact that oncologic outcomes after radical EBRT significantly differ in men with GS 8 versus those with GS 9-10 prostate cancer. We found that EBRT dose was important predictive factor regardless of ADT period. Patients receiving 'non-optimal treatment' (RT doses <78Gy and ADT period <2 years) had the worst treatment outcomes.en_US
dc.language.isoengen_US
dc.relation.isversionof10.1007/s00066-019-01476-zen_US
dc.rightsinfo:eu-repo/semantics/openAccessen_US
dc.subjectPelvic radiotherapyen_US
dc.subjectGrading systemen_US
dc.subjectIntensity modulated radiation therapyen_US
dc.subjectHormonal treatmenten_US
dc.subjectAndrogen deprivation therapyen_US
dc.titleTreatment outcomes of prostate cancer patients with Gleason score 8-10 treated with definitive radiotherapyen_US
dc.typearticleen_US
dc.relation.journalSTRAHLENTHERAPIE UND ONKOLOGIEen_US
dc.identifier.volume195en_US
dc.identifier.issue10en_US
dc.identifier.startpage882en_US
dc.identifier.endpage8293en_US
dc.identifier.wos000511421900003en_US
dc.identifier.scopus2-s2.0-85071184712en_US
dc.contributor.pubmedID31143994en_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergien_US


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record